2. Academic Validation
  3. Accelerated Discovery of Macrocyclic CDK2 Inhibitor QR-6401 by Generative Models and Structure-Based Drug Design

Accelerated Discovery of Macrocyclic CDK2 Inhibitor QR-6401 by Generative Models and Structure-Based Drug Design

  • ACS Med Chem Lett. 2023 Feb 8;14(3):297-304. doi: 10.1021/acsmedchemlett.2c00515.
Yang Yu 1,  Junhong Huang 1,  Hu He 2,  Jing Han 2,  Geyan Ye 1,  Tingyang Xu 1,  Xianqiang Sun 2,  Xiumei Chen 2,  Xiaoming Ren 2,  Chunlai Li 2,  Huijuan Li 2,  Wei Huang 2,  Yangyang Liu 2,  Xinjuan Wang 2,  Yongzhi Gao 2,  Nianhe Cheng 2,  Na Guo 3,  Xibo Chen 3,  Jianxia Feng 4,  Yuxia Hua 4,  Chong Liu 4,  Guoyun Zhu 2,  Zhi Xie 2,  Lili Yao 2,  Wenge Zhong 2,  Xinde Chen 1,  Wei Liu 1,  Hailong Li 2
Affiliations

Affiliations

  • 1 Tencent AI Lab, Tencent, Shenzhen 518057, China.
  • 2 Regor Therapeutics Group, Shanghai, 201210, China.
  • 3 BioDuro-Sundia, Shanghai, 200131, China.
  • 4 BioDuro-Sundia, Beijing, 102200, China.
PMID: 36923916 DOI: 10.1021/acsmedchemlett.2c00515
Abstract

Selective CDK2 inhibitors have the potential to provide effective therapeutics for CDK2-dependent cancers and for combating drug resistance due to high cyclin E1 (CCNE1) expression intrinsically or CCNE1 amplification induced by treatment of CDK4/6 inhibitors. Generative models that take advantage of deep learning are being increasingly integrated into early drug discovery for hit identification and lead optimization. Here we report the discovery of a highly potent and selective macrocyclic CDK2 Inhibitor QR-6401 (23) accelerated by the application of generative models and structure-based drug design (SBDD). QR-6401 (23) demonstrated robust antitumor efficacy in an OVCAR3 ovarian Cancer xenograft model via oral administration.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-153221
    CDK2抑制剂
    CDK
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z